NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Autolus Therapeutics plc (AUTL) Stock Analysis

Autolus Therapeutics plc (AUTL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AUTL

$1.62

−$0.04 (−2.41%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AUTL with… →

AUTL Key Statistics

As of Oct 21, 2026
Trading
Open
$1.69
Previous Close
$1.66
Day's Range
1.61–1.69
52-Week Range
1.18–2.58
Volume
1.83M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.14
Valuation
Market Cap
$431.18M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.67
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.06
Financials (FY)
Revenue (FY)
$75.39M+644.94%
Net Income (FY)
−$287.53M
Profit marginThe share of revenue left as profit after all costs and taxes.
−238.65%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
266.16M
1-Year Return
−0.61%
Dividend and dates
Earnings Date
November 16, 2026
Avg Volume
2.17M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AUTL closed at $1.62, −0.61% over 1 year.

Autolus Therapeutics plc (AUTL) has a market capitalization of $431.18M.

In fiscal 2025, AUTL reported revenue of $75.39M.

AUTL Stock Return by Calendar Year

Autolus Therapeutics plc (AUTL) return since Jun 2018: what $10,000 became

1 year
$10,000 $9,939
−0.61%
5 years
$10,000 $2,798
−72.02%
Since Jun 2018
$10,000 $648
−93.52%

If you had invested $10,000 in Autolus Therapeutics plc (AUTL) at the close on June 22, 2018, the earliest close on record here, it would have been worth $648 at the close on October 21, 2026: −93.52% in total, −28.00% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−18.59%
2025−15.32%
2024−63.51%
2023+238.95%
2022−63.39%
2021−41.95%
2020−32.27%
2019−59.81%
2018 (partial year)+31.36%

As of October 21, 2026.

AUTL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$75.39M−$287.53M−381.4%
2024$10.12M−$220.66M−2,180.5%
2023$1.70M−$208.38M−12,272.3%
2022$6.19M−$148.84M−2,403.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$75.39M−$20.98M−$270.54M−$287.53M−381.4%
2024$10.12M−$1.27M−$241.43M−$220.66M−2,180.5%
2023$1.70M$1.70M−$175.53M−$208.38M−12,272.3%
2022$6.19M—−$142.89M−$148.84M−2,403.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AUTL Valuation vs Biotechnology Median

Median of 608 stocks
MetricAUTLBiotechnology medianvs median
P/S ratio3.6713.300.3x the median
Profit margin−238.65%−38.31%200.3 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Autolus Therapeutics plc (AUTL) at $431.18M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 752.

Over the past 52 weeks the price has ranged from $1.18 to $2.58. The most recent close on file for AUTL is $1.62, dated October 21, 2026. That is −$0.04 (−2.41%) against the previous close. The latest close sits 37.87% above that 52-week low.

Financial Health

In fiscal 2025, Autolus Therapeutics plc reported revenue of $75.39M. Against the prior fiscal year total of $10.12M, that is a change of +644.94%. The same year closed with a net loss of $287.53M. Profit margin runs at −238.65%. That is 200.3 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −1.06.

Across the 4 fiscal years on file, revenue moves from $6.19M in 2022 to $75.39M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 3.67 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 2.14. Daily returns over the trailing 8 years annualize to a volatility of 80.61%. The trailing one-year total return is −0.61%. Across 5 years the annualized return works out at −22.49%.

Growth & Income

No dividend is on file for AUTL.

So far in 2026 the total return is −18.59%. The strongest complete calendar year on file is 2023 at +238.95%; the weakest is 2024 at −63.51%. Of the 7 complete calendar years on file, 1 finished higher.

Peer Comparison

Autolus Therapeutics plc (AUTL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Autolus Therapeutics plc AUTL $431.18M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Autolus Therapeutics plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Visit website →